| Application no. and date | 22724683.2 (espacenet) (Federated) (European Patent Register), 20220421 | | Patent/reg. no. and date | DK/EP 4114465, 20230830 | | Publication date | 20230111 | | Priority no. and date | US 202163178739 P, 20210423, US 202163245285 P, 20210917, US 202163272851 P, 20211028 | | EP pub. no. and date |
EP 4114465 20230111 | | Effective date | | | Applicant/owner | AstraZeneca AB,
151 85 Södertälje, SE | | Applicant ref. no. | 1679367 | | Inventor | LINDHOLM, Catharina,
SE-151 85 Södertälje, SE,
ALMQUIST, Joachim,
SE-151 85 Södertälje, SE,
ROUSE, Tomas,
SE-151 85 Södertälje, SE,
CHIA, Yen Lin,
Wilmington, Delaware 19850-5437, US,
TUMMALA, Rajendra,
Wilmington, Delaware 19850-5437, US,
ROSKOS, Lorin,
Gaithersburg, Maryland 20878, US | | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB
, GB | | Opponent | | | IPC Class | A61K 31/00 (2006.01) , A61K 33/00 (2006.01) , A61K 39/395 (2006.01) , C07K 16/28 (2006.01) | | Title | ANTI-IFNAR1-DOSERINGSPLAN TIL SUBKUTAN INJEKTION | | Int. application no. | EP2022060592 | | Int. publication no. | WO2022223714 | | Related patent (certificate) | | | Status | Rettet DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
